Prohedonic properties of gamma ‐hydroxybutyrate are associated with changes in limbic resting‐state functional connectivity

AbstractObjectiveGamma ‐hydroxybutyrate (GHB) is an endogenous GHB‐/GABA‐B receptor agonist and a narcolepsy treatment. However, GHB is also abused for its prohedonic effects. On a neuronal level, it was shown that GHB increases regional cerebral blood flow in limbic areas such as the right anterior insula (rAI) and the anterior cingulate cortex (ACC). We aimed to further explore the association between the subjective and neuronal signatures of GHB.MethodWe assessed subjective effects and resting ‐state functional connectivity (rsFC) of an rAI‐ and an ACC‐seed in 19 healthy male subjects after GHB (35 mg/kg p.o.) using a placebo‐controlled, double‐blind, randomized, cross‐over functional magnet resonance imaging design.ResultsGHB increased subjective ratings for euphoria (p 
Source: Human Psychopharmacology: Clinical and Experimental - Category: Psychiatry Authors: Tags: RESEARCH ARTICLE Source Type: research

Related Links:

Sleep disturbances such as excessive daytime sleepiness, central and obstructive sleep apneas, restless legs syndrome, and rapid eye movement sleep dysregulation are prominent in patients with myotonic dystrophy type 1 (DM1). Mild intellectual deficits presented in many patients with DM1. In addition, psychosocial issues caused by neuropsychiatric symptoms are a clinical problem. We herein present the cases of four DM1 patients with sleep disturbances and neuropsychiatric symptoms in the preceding stage of clinically significant muscle symptoms. One of the cases exhibited a sleep disorder and neuropsychiatric symptoms befo...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Journal of Clinical Sleep Medicine, Ahead of Print.
Source: Journal of Clinical Sleep Medicine : JCSM - Category: Sleep Medicine Authors: Source Type: research
AbstractPurpose of reviewNarcolepsy type 1 (NT1) is a chronic and disabling sleep disorder due to the loss of hypocretinergic neurons in the lateral hypothalamus pathophysiologically linked to an autoimmune process. Current treatment is symptomatic, and no cure is available to date. Immunotherapy is considered a promising future therapeutic option, and this review discusses the rationale for immunotherapy in narcolepsy, current evidences of its effects, outcome measures, and future directions.Recent findingsA limited number of case reports and uncontrolled small case series have reported the effect of different immunothera...
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research
AbstractPitolisant (Wakix®), an orally available, first-in-class antagonist/inverse agonist of the histamine 3 receptor, is approved in the EU (as of March 2016) for the treatment of narcolepsy with or without cataplexy in adults and in the USA (as of August 2019) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. Pitolisant was demonstrated to have minimal risk of abuse in preclinical and clinical studies, and is the only anti-narcoleptic drug not scheduled as a controlled substance in the USA. The totality of evidence from pivotal and supportive phase III trials suggests that pitolisan...
Source: CNS Drugs - Category: Neurology Source Type: research
Jordan Coomer, from Indiana, suffers from cataplexy, which causes sudden muscle paralysis if she giggles or feels strong emotion. It's a complication of narcolepsy, which can be caused by an infection.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Publication date: Available online 23 January 2020Source: American Journal of Kidney DiseasesAuthor(s): Jennifer Y. So, Karen M. Warburton, Ilene M. RosenDaytime sleepiness, also known as hypersomnolence, is common among patients receiving maintenance dialysis and following successful kidney transplantation. Sleepiness may be secondary to medical comorbid conditions, medication side effect, insufficient sleep syndrome, and sleep-disordered breathing or the result of a primary central disorder of hypersomnolence, such as narcolepsy. Unrecognized and untreated sleep disorders are associated with substantial morbidity and mor...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Authors: Kornum BR, Jennum P PMID: 31961748 [PubMed - as supplied by publisher]
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
DUBLIN, Jan. 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
The European Commission has approved Sunosi, a Jazz Pharmaceuticals sleep disorder treatment. Sunosi was approved, in 75- and 150-milligram doses, to improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea who did not respond to primary sleep apnea therapies such as continuous positive airway pressure. Jazz Pharmaceuticals, which is based in Dublin, Ireland, has major operations in Philadelphia where the company has nearly 200 employees.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conditions:   ADHD;   Narcolepsy Interventions:   Drug: ADAIR 10mg IR capsules;   Drug: Crushed d-amphetamine sulfate IR tablets Sponsor:   Vallon Pharmaceuticals, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Eyes | Narcolepsy | Neurology | Psychiatry | Sexual Abuse | Sleep Medicine | Substance Abuse